On the other hand, recent published data suggest that the Crk-C3G-Rap1 pathway could improve endothelial cell integrity in HCC upon treatment with the anti-tumor compound lenvatinib, facilitating tumor suppression when combined with anti-PD-1 [234]. This evidence concerns the gene CRK and neoplasm.